This statement from KMS sum up all future prospects for company
See, I think basically Biocon has clearly articulated its business strategy by saying that we want to be leaders in biosimilars and therefore we are creating a very robust pipeline on which we are delivering. I think the fact that we have been potentially the first to file in terms of our Trastuzumab biosimilar in the US and the fact that the target date has been provided by US FDA later this year is a very important signal that we are actually in a position to deliver very high quality products to the developing world. And I think this is a very, very important signal because up until now I think there was a lot of concern about whether a company like Biocon can indeed address these very, very large and lucrative market opportunities in Biosimilars and the answer is yes.
I think you will also see from the JAMA publication that they have actually validated Biocon's ability to develop such products. So, I think you have to look at it very positively from that point of view. You also know that globally it is accepted that the next bolus of growth in terms of the pharmaceutical area is going to come from biosimilars. And I think you can clearly see that Biocon is amongst the front runners and we clearly see that Biocon and Mylan are in a very strong position to address these very large opportunities because of the fact that we believe we have a very strong cost competitiveness and we have basically invested in this at the right time. So, I think you have to look at it in that context.
And going forward obviously we are going to invest very strongly in a growing pipeline of biosimilars and we want to be very, very strong in this segment. Now you can also see that Biocon is very unique because we are the only company that actually have [started] both insulins and the biologics. So, I think again this puts us into a very prime position in making ourselves very, very strong and large in this whole context of biosimilars. And then Biocon has also been very prudent in investing in some very important novel biologics and we believe that the next few years will also show you that we will build credibility in these novel biologics as well. So, I think it's a very, very exciting opportunity for Biocon and for investors to invest in such a unique growth story.